Maravai Q2 revenue $242.7M (+11% YoY), net income $156.7M (+17%), Adj. EBITDA margin 78% record

MARAVAI LIFESCIENCES HOLDINGS, INC.

2022-Q2 EPS reported $1.03 revenue$487,025,000

Q2 revenue $242.7M (+11% YoY); net income $156.7M (+17%); Adj. EBITDA $188.5M (78% margin).
Nucleic Acid Production revenue $225.2M (+17% YoY); base business (ex-COVID CleanCap) grew 27%.
Biologics Safety Testing revenue $17.5M (-4% YoY); Protein Detection business sold in Sept 2021.
Leadership additions: Pete Leddy as EVP/CAO, Kate Broderick SVP R&D, Jay Lochhead VP Quality & Regulatory.
Signed DoD cooperative agreement to partly fund Nucleic Acid Production manufacturing expansion in San Diego.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.